Review ArticlesImplications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression
Introduction
This article focuses on the implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. The background will start with a brief review of data on the natural course of unipolar major depression. This review will then include a discussion of several topics: the epidemiology of unipolar major depression; the cumulative probability of time to recovery, including episode duration and likelihood of chronicity; and specification of clinical predictors that increase the risk of a relapse/recurrence after recovery from unipolar major depression. Data will be presented on associated comorbidity, including comparison with data from other chronic and recurrent medical illnesses, and morbidity and mortality from suicide.
Published data will be presented, and recently analyzed findings from the National Institute of Mental Health (NIMH) Collaborative Depression Study (CDS) that have not yet been accepted for publication will be discussed. This paper will also briefly review data on the probability of patients with unipolar major depression to receive the correct treatment in sufficient duration and dosage. The purpose of this review is to quantify the importance of this public health crisis. Furthermore, this review will identify the need, from both a healthcare and economic perspective, to show the efficacy of maintenance treatment for this pernicious and lifelong disorder.
Data from patients in the CDS, and findings from Angst’s long-term prospective study of mood disorders (Angst 1986), will be used to show the consequences of failing to achieve adequate maintenance treatment for unipolar recurrent major depression. Such a failure can have not only psychopathological, but also psychosocial consequences, decreasing work productivity and the quality of a person’s life. The lack of a control group in this study places important caveats on interpreting the data; however, it does give many insights into the natural course in the largest cohort of people whose depression led them to seek inpatient and outpatient treatment in university-based medical centers, and who were then followed up prospectively at short intervals. This cohort has been systematically and comprehensively assessed, at least annually, for a minimum of 18 years. Recent NIMH funding will extend the follow-up to at least 23 years on all subjects.
This paper will then identify and examine the current unresolved questions relating to the maintenance treatment of recurrent unipolar major depression. In doing so, this paper will analyze published data, presented in peer-reviewed journals, on randomized controlled clinical trials of continuation and maintenance studies of recurrent unipolar major depression.
Section snippets
Epidemiology of major depression
The most recent epidemiologic study estimates the lifetime prevalence rate of major depression in the United States at 17.1%, and the rate of unipolar major depression at approximately 16% (Kessler et al 1994). This is consistent with several other epidemiologic studies conducted in different regions of the world since 1988 Weissman et al 1992, Hwu et al 1989.
Morbidity and mortality from unipolar major depression
Available data show that the morbidity and mortality from major depressive disorder and major depressive symptoms are comparable to that
Duration of treatment
What duration of treatment is appropriate for recurrent unipolar major depression? Possible durations include the following: 1) 6 months, the conventional duration of the continuation phase; 2) 1 year, a length supported by at least three continuation studies; 3) 2 years, which is supported by two treatment studies; and 4) 5 years, the duration of one treatment study (Kupfer et al 1992). The 5-year study randomized 20 subjects to active treatment or placebo after they had been maintained in a
Summary
This paper attempts to: 1) present the state of knowledge about long-term treatment of recurrent unipolar major depression; 2) stress the crucial need for continued research in this area; and 3) specify the opportunities for antidepressants that display long-term maintenance efficacy. To answer the unresolved questions presented in this paper, a study would be required with an adequate sample size needed (600–800 subjects) and a reasonable duration of maintenance treatment (3–5 years).
Acknowledgements
The authors acknowledge the invaluable assistance of Ms. Laura Hitt, MA, in the preparation of the manuscript, including literature review and editing of the text.
This work was presented at the Neuroscience Discussion Forum “A Decade of Serotonin Research” held at Amelia Island, Florida in November 1997. The conference was sponsored by the Society of Biological Psychiatry through an unrestricted educational grant provided by Eli Lilly and Company.
References (45)
Compliance during treatment with antidepressants
J Affect Disord
(1997)- et al.
Comparison of full dose versus half dose pharmacotherapy in the maintenance treatment of recurrent depression
J Affect Disord
(1993) - et al.
Suicidal children grow upDemographic and clinical risk factors for adolescent suicide attempts
J Am Acad Child Adolesc Psychiatry
(1991) The course of major depression, atypical bipolar disorder, and bipolar disorder
- et al.
The course of monopolar depression and bipolar psychoses
Psychiatr Neurol Neurochir
(1973) - et al.
Outcome studies of depression in adulthood
NIMH/NIH Consensus Development Conference Statement. Mood disordersPharmacological prevention of recurrences
Am J Psychiatry
(1985)- et al.
Sertraline in the prevention of depression
Br J Psychiatry
(1992) - et al.
Three-year outcomes for maintenance therapies in recurrent depression
Arch Gen Psychiatry
(1990) - et al.
Conceptualization and rationale for consensus definitions of terms in major depressive disorderRemission, recovery, relapse, and recurrence
Arch Gen Psychiatry
(1991)
Suicide and primary affective disorders
Br J Psychiatry
A rating scale of depression
J Neurol Neurosurg Psychiatry
The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
JAMA
Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule
Acta Psychiatr Scand
IntroductionOverview of the clinical studies program
Am J Psychiatry
Depression underrecognition and undertreatment by psychiatrists and other health care professionals
Arch Intern Med
The difficult depressed patient in perspective
J Clin Psychiatry
“Double depression”Superimposition of acute depressive episodes on chronic depressive disorders
Am J Psychiatry
Recovery in major depressive disorderAnalysis with the life table and regression models
Arch Gen Psychiatry
Cited by (256)
Perspectives on the course of major depression: Trajectories of remission and relapse with CBT or no treatment
2022, Journal of Behavioral and Cognitive TherapyCitation Excerpt :Indeed, three major epidemiologic surveys identify three months as the median episode length (Eaton et al., 1997; Spijker et al., 2002; Üstün & Kessler, 2002). Yet, an estimated 25–40% of individuals experience a relapse or recurrence within two years (Lavori, Dawson, & Mueller, 1994), increasing up to 75% after 10 years, and 87% after 15 years (Keller & Boland, 1998). Therefore, although the most pressing task for clinicians is attending to the index episode and achieving symptom and impairment reduction, management of depression in clinical practice often involves attention to residual symptoms, maintenance of treatment gains, and episode recurrence.
More treatment but no less depression: The treatment-prevalence paradox
2022, Clinical Psychology ReviewThe search for rapid acting antidepressants: Research synthesis and perspectives
2019, Neurobiology of Depression: Road to Novel TherapeuticsInternet- and mobile-based aftercare and relapse prevention in mental disorders: A systematic review and recommendations for future research
2018, Internet InterventionsCitation Excerpt :Mirroring the frequent comorbidity and commonalities of mental disorders (Kessler et al., 2011a; Kessler et al., 2011b), most studies were designed transdiagnostic, targeting occupational rehabilitation (Bischoff et al., 2013; Zwerenz et al., 2017a), individual self-management strategies (Ebert et al., 2013; Välimäki et al., 2017) or comorbid mental symptoms of severe somatic diseases (Norlund et al., 2018; Willems et al., 2017a). Disorder-specific interventions targeted affective and eating disorders, reflecting their frequent recurrences and risk of chronification (Keller and Boland, 1998; McFarlane et al., 2008). The limited amount of studies eligible for inclusion did not allow to draw conclusions about the efficacy of IMIs as aftercare or follow-up interventions for mental disorders.